Hormone markers in pituitary adenomas: changes within last decade resulting from improved method

Area of Science:

• Endocrinology
• Pathology
• Immunohistochemistry

Background:

• Pituitary adenomas are common tumors affecting hormone production.
• Accurate classification relies on identifying hormone expression within tumors.
• Traditional polyclonal antibodies have limitations in specificity.

Purpose of the Study:

• To compare the diagnostic significance of polyclonal antibodies versus monoclonal antibodies (MAbs) for demonstrating hormone expression in pituitary adenomas.
• To evaluate the impact of antibody type on adenoma classification accuracy.

Main Methods:

• Retrospective analysis of two series of pituitary adenomas (n=166 with polyclonal, n=572 with MAbs).
• Classification based on light microscopy, immunostaining for pituitary hormones, and electron microscopy.
• Comparison of type-specific and additional hormone expression rates between antibody types.

Main Results:

• Monoclonal antibodies identified typical hormone expression in 91.1% of adenomas, versus 63.2% with polyclonal antibodies.
• Adenomas stained with MAbs showed additional or atypical hormone expression in only 8.9% of cases, compared to 36.7% with polyclonal antibodies.
• MAbs demonstrated a clearer distinction in hormone expression patterns.

Conclusions:

• Monoclonal antibodies provide superior specificity and clarity for immunostaining pituitary hormones.
• MAbs are recommended for more accurate and reliable classification of pituitary adenomas.
• The improved diagnostic performance of MAbs enhances understanding of pituitary tumor heterogeneity.